2024-514032-25-00招募中2 期
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 72
- 试验地点
- 31
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Isabelle RAY-COQUARD
Scientific
Asso De Recherche Cancers Gynecologiques
研究点 (31)
Loading locations...
相似试验
进行中（未招募）
不适用
A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABELCLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN APROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVEREGIMEN IN KIDNEY TRANSPLANT SUBJECTS.Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4)) - Short Title: OSAKA StudyProphylaxis of rejection in kidney allograft recipients (via immunosuppression)MedDRA version: 9.1Level: LLTClassification code 10023438Term: Kidney transplantEUCTR2007-005376-13-NLAstellas Pharma Europe Ltd.1,200
进行中（未招募）
不适用
A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABELCLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN APROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVEREGIMEN IN KIDNEY TRANSPLANT SUBJECTS.Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4)) - Short Title: OSAKA StudyProphylaxis of rejection in kidney allograft recipients (via immunosuppression)MedDRA version: 9.1Level: LLTClassification code 10023438Term: Kidney transplantEUCTR2007-005376-13-IEAstellas Pharma Europe Ltd.1,200
进行中（未招募）
不适用
A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABELCLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN APROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVEREGIMEN IN KIDNEY TRANSPLANT SUBJECTS.Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4)) - Short Title: OSAKA StudyProphylaxis of rejection in kidney allograft recipients (via immunosuppression)MedDRA version: 9.1Level: LLTClassification code 10023438Term: Kidney transplantEUCTR2007-005376-13-ATAstellas Pharma Europe Ltd.1,200
进行中（未招募）
1 期
A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABELCLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN APROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVEREGIMEN IN KIDNEY TRANSPLANT SUBJECTS.Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4)) - Short Title: OSAKA StudyEUCTR2007-005376-13-SKAstellas Pharma Europe Ltd.1,200
进行中（未招募）
不适用
A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABELCLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN APROGRAF®-/ ADVAGRAF®-BASED IMMUNOSUPPRESSIVEREGIMEN IN KIDNEY TRANSPLANT SUBJECTS.Protocol for Phase IIIb Study of Advagraf® (FK506E (MR4)) - Short Title: OSAKA StudyProphylaxis of rejection in kidney allograft recipients (via immunosuppression)MedDRA version: 9.1Level: LLTClassification code 10023438Term: Kidney transplantEUCTR2007-005376-13-PTAstellas Pharma Europe Ltd.1,200